Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Lourdes Gutierrez-Xicotencatl"'
Publikováno v:
Microorganisms, Vol 11, Iss 6, p 1609 (2023)
Human papillomavirus (HPV) infection is associated with precancerous lesions and cancer of the genital tract both in women and men. The high incidence of cervical cancer worldwide focused the research on this infection mainly in women and to a lesser
Externí odkaz:
https://doaj.org/article/4287d656feef4615bee998e11abb0b26
Autor:
Oscar Badillo-Godinez, Adolfo Pedroza-Saavedra, Veronica Valverde-Garduño, Victor Bermudez-Morales, Minerva Maldonado-Gama, Ricardo Leon-Letelier, Laura C. Bonifaz, Fernando Esquivel-Guadarrama, Lourdes Gutierrez-Xicotencatl
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
HPV E5 is an oncoprotein mainly expressed in premalignant lesions, which makes it an important target for a vaccine to prevent or cure cervical cancer (CC). In this study, we evaluated whether E5 targeted to DEC-205, present in dendritic cells (DCs),
Externí odkaz:
https://doaj.org/article/bc274769c60343f3ab2afbcb2cb51d18
Autor:
Herbey O. Padilla-Quirarte, Delia V. Lopez-Guerrero, Lourdes Gutierrez-Xicotencatl, Fernando Esquivel-Guadarrama
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
The influenza A virus infection continues to be a threat to the human population. The seasonal variation of the virus and the likelihood of periodical pandemics caused by completely new virus strains make it difficult to produce vaccines that efficie
Externí odkaz:
https://doaj.org/article/a1c7c573b77041d89b91013254436ea1
Autor:
Adolfo Pedroza-Saavedra, Angelica Nallelhy Rodriguez-Ocampo, Azucena Salazar-Piña, Aislinn Citlali Perez-Morales, Lilia Chihu-Amparan, Minerva Maldonado-Gama, Aurelio Cruz-Valdez, Fernando Esquivel-Guadarrama, Lourdes Gutierrez-Xicotencatl
Publikováno v:
Vaccines, Vol 9, Iss 5, p 442 (2021)
Antibodies against the Human Papillomavirus (HPV) L1 protein are associated with past infections and related to the evolution of the disease, whereas antibodies against L1 Virus-Like Particles (VLPs) are used to follow the neutralizing antibody respo
Externí odkaz:
https://doaj.org/article/0b800d5c53cf4a398f5234106dccf3b2
Autor:
Laura Antonio-Herrera, Oscar Badillo-Godinez, Oscar Medina-Contreras, Araceli Tepale-Segura, Alberto García-Lozano, Lourdes Gutierrez-Xicotencatl, Gloria Soldevila, Fernando R. Esquivel-Guadarrama, Juliana Idoyaga, Laura C. Bonifaz
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
CD4+ T cells are major players in the immune response against several diseases; including AIDS, leishmaniasis, tuberculosis, influenza and cancer. Their activation has been successfully achieved by administering antigen coupled with antibodies, again
Externí odkaz:
https://doaj.org/article/847f746cb30c4536a88602ea70c5fc13
Autor:
Angelica Nallelhy Rodriguez-Ocampo, Aurelio Cruz-Valdez, Lourdes Gutierrez-Xicotencatl, Lilia Chihu-Amparan, Fernando Esquivel-Guadarrama, Adolfo Pedroza-Saavedra, Minerva Maldonado-Gama, Azucena Salazar-Piña, Aislinn Citlali Perez-Morales
Publikováno v:
Vaccines
Volume 9
Issue 5
Vaccines, Vol 9, Iss 442, p 442 (2021)
Volume 9
Issue 5
Vaccines, Vol 9, Iss 442, p 442 (2021)
Antibodies against the Human Papillomavirus (HPV) L1 protein are associated with past infections and related to the evolution of the disease, whereas antibodies against L1 Virus-Like Particles (VLPs) are used to follow the neutralizing antibody respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41aba28b36150f7f443383bcb09a7d26
http://europepmc.org/articles/PMC8147477
http://europepmc.org/articles/PMC8147477
Autor:
Nohemi Camacho-Concha, Amiel Olivos-Ortiz, Alfredo Nuñez-Rivera, Adolfo Pedroza-Saavedra, Lourdes Gutierrez-Xicotencatl, Yvonne Rosenstein, Gustavo Pedraza-Alva
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80806 (2013)
In normal tissues, strict control of tissue size is achieved by regulating cell numbers. The mechanism that controls total cell number is known as contact inhibition of growth and it depends on the NF2/Merlin pathway. Negative regulation of this path
Externí odkaz:
https://doaj.org/article/a20107cf89ea4e17b4e37484edb4b923
Autor:
Adolfo Pedroza-Saavedra, Veronica Valverde-Garduño, Ricardo Leon-Letelier, Oscar Badillo-Godinez, Laura C. Bonifaz, Victor Bermudez-Morales, Lourdes Gutierrez-Xicotencatl, Fernando Esquivel-Guadarrama, Minerva Maldonado-Gama
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
HPV E5 is an oncoprotein mainly expressed in premalignant lesions, which makes it an important target for a vaccine to prevent or cure cervical cancer (CC). In this study, we evaluated whether E5 targeted to DEC-205, present in dendritic cells (DCs),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9653f704b8766fc6af7050f0cc0f2eda
https://pubmed.ncbi.nlm.nih.gov/33717073
https://pubmed.ncbi.nlm.nih.gov/33717073
Autor:
Lilia Chihu-Amparan, Azucena Salazar-Piña, Minerva Maldonado-Gama, Fernando Esquivel-Guadarrama, Lourdes Gutierrez-Xicotencatl, Adolfo Pedroza-Saavedra
Publikováno v:
Molecular cancer research : MCR. 19(2)
The human papillomavirus (HPV) is recognized as the main etiologic agent associated with cervical cancer. HPVs are epitheliotropic, and the ones that infect the mucous membranes are classified into low-risk (LR) and high-risk (HR) types. LR-HPVs prod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b301e9f79cc1ad1839448ec06e5c6fe
https://pubmed.ncbi.nlm.nih.gov/33106372
https://pubmed.ncbi.nlm.nih.gov/33106372
Autor:
Delia V. Lopez-Guerrero, J.C. Villegas-Garcia, Fernando Esquivel-Guadarrama, N. Arias, Gladys Fernández, A. González, Gabriela Rosas-Salgado, Oscar Badillo-Godinez, Susana López, Adolfo Pedroza-Saavedra, Lourdes Gutierrez-Xicotencatl, Lilia Chihu-Amparan
Publikováno v:
Vaccine. 36:3072-3078
VP2/VP6 virus like particles (VLPs) are very effective in inducing protection against the rotavirus infection in animal models. Individually, VP6 can also induce protection. However, there is no information about the immunogenicity of VP2. The aim of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ed20e7104e9d7cd72ef5dbc61f3f3e
https://doi.org/10.1016/j.vaccine.2017.03.104
https://doi.org/10.1016/j.vaccine.2017.03.104